Although the trial that targets Factor D did not meet efficacy endpoints in geographic atrophy (GA) secondary to age-related macular degeneration (73), it demonstrated the feasibility of targeting alternative pathway proteins in retina. This evidence concerns the gene LIF and age-related macular degeneration.